##  [New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender](/us-en/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender-0 "New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender") 

  Nov 13, 2020